









VIEWPOINTS

Basic Science in Movement Disorders: Fueling the Engine of Translation into Clinical Practice

Tiago F. Outeiro, PhD,^{1,2,3,4}  Lorraine V. Kalia, MD, PhD,^{5,6,7}  Erwan Bezard, PhD,^{8,9}  Juan Ferrario, PhD,¹⁰ 
 Chin-Hsien Lin, MD, PhD,^{11,12,13} Mohamed Salama, MD, PhD,^{14,15} David G. Standaert, MD, PhD,¹⁶
 Lolade Taiwo, M.B.ChB, MSc, FMCP,¹⁷ Ryosuke Takahashi, MD, PhD,¹⁸  Miquel Vila, MD, PhD,^{19,20,21} 
 Brit Mollenhauer, MD,^{4,21,22}  Per Svenningsson, MD, PhD,^{21,23,24*}  and
 The MDS Basic Science Special Interest Group Steering Committee

¹Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center Göttingen, Göttingen, Germany

²Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany

³Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle upon Tyne, UK

⁴Scientific employee with an honorary contract at Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Göttingen, Germany

⁵Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, Canada

⁶Division of Neurology, Department of Medicine, University of Toronto, Toronto, Canada

⁷Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada

⁸Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France

⁹Centre National de la Recherche Scientifique Unité Mixte de Recherche 5293, Institut des Maladies Neurodégénératives, Bordeaux, France

¹⁰Universidad de Buenos Aires, Facultad de Ciencias Exactas y Naturales, Instituto de Biociencias, Biotecnología y Biología traslacional (iB3) and CONICET, Buenos Aires, Argentina

¹¹Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan

¹²Institute of Molecular Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan

¹³Department of Biomedical Engineering, National Taiwan University, Taipei, Taiwan

¹⁴Institute of Global Health and Human Ecology, The American University in Cairo, Cairo, Egypt

¹⁵Faculty of Medicine, Mansoura University, Dakahleya, Egypt

¹⁶Department of Neurology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA

¹⁷Department of Neurology, University College Hospital, Ibadan, Nigeria

¹⁸Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan

¹⁹Neurodegenerative Diseases Research Group, Vall d'Hebron Research Institute (VHIR), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Autonomous University of Barcelona (UAB), Barcelona, Spain

²⁰Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain

²¹Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, Maryland, USA

²²Paracelsus-Elena-Klinik, Kassel, Germany; University Medical Center Goettingen, Institute of Neurology, Goettingen, Germany

²³Department of Clinical Neuroscience and Neurology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

²⁴Department of Basic and Clinical Neuroscience, King's College London, London, UK

ABSTRACT: Basic Science is crucial for the advancement of clinical care for Movement Disorders. Here, we provide brief updates on how basic science is important for understanding disease mechanisms, disease prevention, disease diagnosis, development of novel therapies and to establish the basis for personalized medicine. We conclude the viewpoint by a call to action to further

improve interactions between clinician and basic scientists. © 2024 The Authors. *Movement Disorders* published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Key Words: basic science; Parkinson's disease; movement disorders; translational research

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

***Correspondence to:** Per Svenningsson, Department of Clinical Neuroscience, Karolinska Institutet, 17177, Stockholm, Sweden. E-mail: per.svenningsson@ki.se

Relevant conflicts of interest/financial disclosures: The authors do not report any conflict of interest related to this article.

Funding agency: N/A.

Received: 21 February 2024; **Revised:** 11 March 2024; **Accepted:** 15 March 2024

Published online in Wiley Online Library
[wileyonlinelibrary.com](https://www.wileyonlinelibrary.com). DOI: 10.1002/mds.29802

Since the founding of movement disorders as a neurology subspecialty, basic science research has been instrumental for understanding pathophysiology and for advancing the technologies available to diagnose and treat these neurological diseases. In this way, the work of basic scientists in the laboratory has fueled the engine that drives clinical developments and can be viewed as complementary to the efforts of neurologists in the clinic to improve the daily life of those affected by movement disorders.

Striking examples of how synergies between basic science and clinical research have transformed everyday practice in a movement disorders clinic include the development of levodopa for treatment of Parkinson's disease (PD),¹ including Nobel Prize-winning work,² and the use of deep brain stimulation (DBS) for treatment of multiple movement disorders, based on research awarded the Lasker Prize.³ The discoveries that led to both clinical mainstays required a back-and-forth between the bench and the bedside; for example, the clinical discovery of MPTP-induced parkinsonism⁴ led to the development of animal models⁵ that enabled physiologists to test working hypotheses related to DBS.⁶ Additional examples of commonplace clinical activities that required basic science for their discovery and development include the use of recombinant botulinum toxin as a therapy⁷ and the application of molecular biology-based techniques for the diagnoses of a wide range of genetic movement disorders.

With science and technology advancing at an accelerated pace, continued groundbreaking discoveries in basic science research are expected to enhance patient care for individuals affected by movement disorders in the coming years. In this context, a breadth of initiatives are needed to facilitate and bolster the connections between basic and clinical specialists. As an example of such initiatives, the International Parkinson and Movement Disorder Society (MDS) Basic Science Special Interest Group was established to contribute to the training and updating of clinical neurologists and neuroscientists on the forefront of research related to genetics, imaging, biomarkers, preclinical models, and pathophysiological mechanisms of movement disorders and their therapies.⁸ In this Viewpoint, we discuss how basic science plays an instrumental role in contributing to our understanding of disease mechanisms, preventive strategies, diagnoses, therapy development, and personalized medicine of movement disorders now and in the future.

Basic Science for Understanding Disease Mechanisms

Understanding the underlying mechanisms of movement disorders through basic research helps unravel the complex interplay between genetic, environmental,

and lifestyle factors that contribute to their development. This knowledge enables the identification of potential risk factors, illuminating our understanding of disease progression, and provides insights into novel therapeutic targets. For instance, genetic discoveries have been instrumental for our understanding of genes and pathways implicated in movement disorders. This has enabled basic researchers to test hypotheses using a variety of disease models, ranging from simple cell models to more complex animal models.⁹ Further, genetic discoveries have been leveraged by both academic and industry researchers for therapeutic development.

Advances in molecular biology technologies will continue to allow for more of the genome to be explored in a larger number of individuals, including those that have been underrepresented in the study of movement disorders.¹⁰ Likewise, such advances will enable us to further interrogate the contribution of epigenetics and epitranscriptomics to the modulation of gene expression at the single-cell level.¹¹ Moreover, studies in human induced pluripotent stem cells (iPSC) and in organoids will also provide pathophysiological insights into distinct movement disorders.¹²

Advances in artificial intelligence (AI) and in machine learning algorithms for studying 'big data', including various 'omics' (eg, genomics, epigenomics, transcriptomics, proteomics, lipidomics, metabolomics) and imaging data, will continue to facilitate breakthroughs in several areas. An example at the molecular level is the ability to predict protein structure using approaches such as AlphaFold2, which represents a leap forward in our ability to develop drugs to specifically target proteins involved in pathogenic pathways.¹³ With AI-guided gene editing,¹⁴ the discovery of small molecules¹⁵ or targeted protein degradation technologies¹⁶ is evolving at an incredibly rapid pace. This will expedite new discoveries of disease mechanisms and the development of novel treatment strategies.

Basic Science and Disease Prevention

Basic science research is instrumental in identifying potential risk factors and understanding the early stages of movement disorders. By elucidating the molecular, cellular, and physiological changes that occur prior to the onset of the typical disease features, researchers can explore strategies for early detection and interventions to delay or prevent the disease altogether. This knowledge can inform public health policies, lifestyle recommendations, and targeted interventions to reduce the overall burden of movement disorders. For example, exercise and nutrition are emerging as important lifestyle factors that can influence the progression of PD.¹⁷

The groundbreaking discoveries in the 1990s that first implicated α -synuclein (α Syn) in PD^{18,19} opened a whole field of research that is still bearing fruit. For example, tools developed from basic science discoveries – such as α Syn seed amplification assays (α Syn-SAA),²⁰ which evolved from our understanding of the process of α Syn aggregation kinetics in vitro – are allowing for the identification of earlier stages of PD when these interventions and others could potentially prevent or delay the onset of PD.^{21,22} In the same way, the combination of epidemiological and basic science data has recently shed light on the possible role of pesticide exposure in increasing the susceptibility for developing PD,²³ and provided the evidence needed to advocate for changes in governmental policies. Back translating clinical findings into laboratory models will, in turn, enable scientists to decipher the molecular mechanisms underlying the effects observed.

Basic Science and Disease Diagnosis

Basic science research has helped tremendously in developing diagnostic tools and criteria for movement disorders. For instance, by studying the underlying molecular mechanisms and early signs and symptoms, researchers have been able to advance biomarkers associated with PD that promise to differentiate PD from other similar conditions, thereby improving diagnostic accuracy. α Syn-SAA have been developed based on the early discovery made by basic scientists that recombinant α Syn forms fibrils in vitro, as mentioned above,²⁴ together with basic science research in the prion field that identified seeding properties of aggregation-prone proteins.^{25,26} Through several iterations, α Syn-SAA capable of identifying seed-competent α Syn in cerebrospinal fluid, skin, or blood²⁷ of individuals with a synucleinopathy are being established and making their path towards clinical practice.²⁰ This recent progress illustrates how current efforts to implement biological markers can impact improved disease classification and staging systems of PD.^{21,22,28}

On a separate front, efforts by physicists have resulted in the development of magnetic resonance imaging sequences that can detect neuromelanin-like signals²⁹ and of magnetic resonance spectroscopy to detect glucose and neurotransmitter metabolism alterations,³⁰ providing additional disease-specific information that could help in stratifying study populations and providing clinical endpoints for judging the effects of new therapies. Excitingly, chemists have recently identified first-generation α Syn positron emission tomography tracers that promise to revolutionize the way we study and diagnose synucleinopathies.^{31,32} Thus, there is great hope that these imaging approaches will, hopefully, complement the currently used dopamine

imaging in the clinical setting in the near future. Further, clinical neurophysiological studies using both invasive (eg, DBS) and non-invasive brain stimulation techniques could aid in refining the diagnosis, localization, and patient-specific targets with symptom-specific stimulation parameters and facilitate the development of novel therapies in movement disorders.³³

Basic Science and the Development of Novel Therapies

Understanding movement disorders' basic mechanisms is the only road for rationalizing targeted therapeutics. In this context, basic research helps identify specific molecular pathways, neurotransmitter systems, brain circuitries, and genetic factors involved in disease. This combined knowledge forms the basis for developing novel drugs, gene and cell replacement therapies, and other interventions aimed at modifying disease progression, alleviating symptoms, and improving patients' quality of life. Neurodegenerative diseases such as Huntington's disease (HD) tend now to be considered as neurodevelopmental disorders, eventually provoking neurodegeneration.³⁴ Multiple strategies have recently been applied to the development of targeted therapy for HD, including antisense oligonucleotides which would not be possible without the basic science understanding of RNA silencing.³⁵ For PD, the first large clinical trials targeting α Syn^{36,37} with many expected over the upcoming years, are all based on more than 25 years of basic science research focused on the role of α Syn in PD.

Importantly, the design of clinical trials is increasingly guided by our understanding of the underlying pathobiology of disease. While there have been numerous successes for symptomatic therapies in movement disorders, there have been few thus far for disease-modifying therapies. Regardless, negative clinical trials are valuable in our understanding of the basic mechanisms of disease and, in this context, the back-and-forth between the bench and the bedside should continue as a major goal in the field. Advances in clinical design are anticipated to accelerate the translation from innovative basic science discoveries to the actual clinical testing.

Basic Science as the Basis for Personalized Medicine

Movement disorders, such as PD, are heterogeneous disorders likely with different biological subtypes. Therefore, it is important to define the biological basis of each movement disorder,³⁸ as it is highly plausible that patients may respond differently to different treatments. Basic science efforts should enable the identification of biomarkers and




FIG. 1. The relationship between basic science research and clinical care for movement disorders. [Color figure can be viewed at wileyonlinelibrary.com]

genetic factors that can help distinguish different types of movement disorders and predict individual responses to specific therapies. This knowledge has the potential to guide clinicians in tailoring treatment plans to each patient’s unique characteristics, leading to more personalized and effective care.

Call to Action

In summary, basic science is essential to clinical practice in general, and many examples in movement disorders are true demonstrations of the indissociable relationship between the two for improving healthcare. Basic science informs diagnosis, treatment development, personalized medicine, understanding disease mechanisms, disease progression, and the development of preventive strategies. While basic science still does not answer all open questions in the field of movement disorders, it is undeniable that by bridging the gap between laboratory findings and clinical applications, basic science research enhances patient care and improves outcomes for individuals affected by movement disorders.

Despite the clear contributions of basic science to clinical practice, communication between researchers in both fields has happened mainly via scientific publications. Basic science aspects are increasing in complexity, and it is not always feasible for those in the clinic to remain in

step with the rapid advances being made in the laboratory. Thus, we argue that additional collaborative efforts must be pursued to take full advantage of the potential impact of an even closer interaction (Fig. 1). Optimized communication – for example, through combined scientific meetings where both sides explain their fields and plan joint implementation, through joint translational training programs of professionals (such as MD/PhD training) that can then easily bridge between the two fields, and through fostering exchange programs for clinicians to work in a basic science laboratory and for basic scientists to participate in the clinic – are all measures that need to be considered. Engaging the next generation of researchers is crucial as this will foster the incorporation of fresh perspectives from both young clinicians and basic scientists, stimulating groundbreaking ideas, particularly with their adaptability and eagerness to learn. These are not always easy to implement, as clinicians tend to be overstretched in their clinical duties, and basic scientists are tied to tight schedules to complete their experiments and training programs, but finding ways to bolster the interactions between the two domains worldwide will be ever more important for advancing translational research, promoting further understanding of disease mechanisms, and more successful applications in clinical practice. ■

Acknowledgments: We acknowledge the additional members of the MDS Basic Science Special Interest Group: Marie Davis, Sara Elfarrah,

Young-Eun Kim, Eiko N. Minakawa, Esther Sammler, Kaviraja Udupa. We thank Shelby Shuster for her assistance in coordination of the group meetings and preparation of the manuscript. T.F.O. is supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy – EXC 2067/1-390729940*. L.V.K. holds the Wolfond-Krembil Chair in Parkinson's Disease Research. E.B. has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (Grant Agreement No. #951294).

Data Availability Statement

Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.

References

- Lees AJ, Tolosa E, Olanow CW. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr. *Mov Disord* 2015;30(1):19–36. <https://doi.org/10.1002/mds.26120>
- Carlsson A, Lindqvist M, Magnusson T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. *Nature* 1957; 180(4596):1200.
- Olanow CW, Obeso J. Profile of Mahlon DeLong and Alim Benabid, 2014 Lasker-DeBakey medical research awardees. *Proc Natl Acad Sci U S A* 2014;111(50):17693–17695.
- Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. *Science* 1983;219(4587):979–980. <https://doi.org/10.1126/science.6823561>
- Burns RS, Chiu CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. *Proc Natl Acad Sci U S A* 1983;80(14):4546–4550. <https://doi.org/10.1073/pnas.80.14.4546>
- Bergman H, Wichmann T, DeLong MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. *Science* 1990; 249(4975):1436–1438. <https://doi.org/10.1126/science.2402638>
- Cardoso F. Botulinum toxin in parkinsonism: the when, how, and which for botulinum toxin injections. *Toxicon* 2018;147:107–110.
- Basic Science SIG. International Parkinson and Movement Disorder Society; Accessed February 8, 2024. <https://www.movementdisorders.org/MDS/About/Groups/Special-Interest-Groups/Basic-Science.htm>.
- Outeiro TF, Heutink P, Bezard E, Cenci AM. From iPSC cells to rodents and nonhuman primates: filling gaps in modeling Parkinson's disease. *Mov Disord* 2021;36(4):832–841.
- Schumacher-Schuh AF, Bieger A, Okunoye O, et al. Underrepresented populations in Parkinson's genetics research: current landscape and future directions. *Mov Disord* 2022;37(8):1593–1604.
- Tian W, Zhou J, Bartlett A, et al. Single-cell DNA methylation and 3D genome architecture in the human brain. *Science* 2023; 382(6667):eadf5357.
- Bose A, Petsko GA, Studer L. Induced pluripotent stem cells: a tool for modeling Parkinson's disease. *Trends Neurosci* 2022;45(8):608–620.
- Outeiro TF, Vieira TCRG. AI and protein structure and function in neurological disease: relevance to disease management. *Nat Rev Neurol* 2023;19(8):453–454.
- Duan W, Urani E, Mattson MP. The potential of gene editing for Huntington's disease. *Trends Neurosci* 2023;46(5):365–376.
- Jennings D, Huntwork-Rodriguez S, Henry AG, et al. Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease. *Sci Transl Med* 2022;14(648):eabj2658.
- Zimprich A. LRRK2 PROTAC degraders as a potential novel targeting strategy for Parkinson's disease? *Mov Disord* 2022;37(11): 2193.
- Tosefsky KN, Zhu J, Wang YN, Lam JST, Cammalleri A, Appel-Cresswell S. The role of diet in Parkinson's disease. *J Parkinsons Dis* 2024;1–14. <https://doi.org/10.3233/JPD-230264>. Epub ahead of print.
- Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. *Science* 1997;276(5321):2045–2047. <https://doi.org/10.1126/science.276.5321.2045>
- Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. *Nature* 1997; 388(6645):839–840. <https://doi.org/10.1038/42166>
- Siderowf A, Concha-Marambio L, Lafontant DE, et al. Assessment of heterogeneity among participants in the Parkinson's progression markers initiative cohort using α -synuclein seed amplification: a cross-sectional study. *Lancet Neurol* 2023;22(5):407–417.
- Höglinger GU, Adler CH, Berg D, et al. A biological classification of Parkinson's disease: the SynNeurGe research diagnostic criteria. *Lancet Neurol* 2024;23(2):191–204.
- Simuni T, Chahine LM, Poston K, et al. A biological definition of neuronal α -synuclein disease: towards an integrated staging system for research. *Lancet Neurol* 2024;23(2):178–190.
- Paul KC, Krolewski RC, Lucumi Moreno E, et al. A pesticide and iPSC dopaminergic neuron screen identifies and classifies Parkinson-relevant pesticides. *Nat Commun* 2023;14(1):2803.
- Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. *Nat Med* 1998;4(11):1318–1320.
- Prusiner SB. Prions. *Proc Natl Acad Sci U S A* 1998;95(23):13363–13383. <https://doi.org/10.1073/pnas.95.23.13363>
- Caughey B, Baron GS. Prions and their partners in crime. *Nature* 2006;443(7113):803–810. <https://doi.org/10.1038/nature05294>
- Okuzumi A, Hatano T, Matsumoto G, et al. Propagative α -synuclein seeds as serum biomarkers for synucleinopathies. *Nat Med* 2023; 29(6):1448–1455.
- Cardoso F, Goetz CG, Mestre TA, et al. A statement of the MDS on biological definition, staging, and classification of Parkinson's disease. *Mov Disord* 2024;39(2):259–266. <https://doi.org/10.1002/mds.29683>
- Mitchell T, Lehericy S, Chiu SY, Strafella AP, Stoessl AJ, Vaillancourt DE. Emerging neuroimaging biomarkers across disease stage in Parkinson disease: a review. *JAMA Neurol* 2021;78(10): 1262–1272.
- Bednarik P, Goranovic D, Svatkova A, et al. 1H magnetic resonance spectroscopic imaging of deuterated glucose and of neurotransmitter metabolism at 7 T in the human brain. *Nat Biomed Eng* 2023;7(8): 1001–1013.
- Matsuoka K, Ono M, Takado Y, et al. High-contrast imaging of α -synuclein pathologies in living patients with multiple system atrophy. *Mov Disord* 2022;37(10):2159–2161.
- Smith R, Capotosti F, Schain M, et al. The α -synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases. *Nat Commun* 2023;14(1):6750.
- Chen R, Berardelli A, Bhattacharya A, et al. Clinical neurophysiology of Parkinson's disease and parkinsonism. *Clin Neurophysiol Pract* 2022;7:201–227.
- Braz BY, Wennagel D, Ratié L, et al. Treating early postnatal circuit defect delays Huntington's disease onset and pathology in mice. *Science* 2022;377(6613):eabq5011.
- Bennett CF, Kordasiewicz HB, Cleveland DW. Antisense drugs make sense for neurological diseases. *Annu Rev Pharmacol Toxicol* 2021;61:831–852.
- Pagano G, Taylor KI, Anzures-Cabrera J, et al. Trial of prasinezumab in early-stage Parkinson's disease. *N Engl J Med* 2022;387(5):421–432.
- Lang AE, Siderowf AD, Macklin EA, et al. Trial of cinpanemab in early Parkinson's disease. *N Engl J Med* 2022;387(5):408–420.
- Outeiro TF, Alcalay RN, Antonini A, et al. Defining the riddle in order to solve it: there is more than one "Parkinson's disease". *Mov Disord* 2023;38(7):1127–1142.

SGML and CITI Use Only DO NOT PRINT

Author Roles

(1) Research Project: A. Conception, B. Organization, C. Execution; (2) Manuscript Preparation: A. Writing of First Draft, B. Review and Critique.

T.F.O.: 1A, 1B, 1C, 2A, 2B.

L.V.K.: 1A, 1B, 1C, 2A, 2B.

E.B.: 1A, 2A, 2B.

J.F.: 1A, 2B.

C.-H.L.: 2B.

M.S.: 2B.

D.G.S.: 1A, 2A, 2B.

L.T.: 2B.

R.T.: 1A, 2B.

M.V.: 1A, 2A, 2B.

B.M.: 1A, 1B, 1C, 2A, 2B.

P.S.: 1A, 1B, 1C, 2A, 2B.

Financial Disclosures

L.V.K. has received research support from Canadian Institutes of Health Research (CIHR), Cure Parkinson's, Krembil Foundation, The Michael J. Fox Foundation for Parkinson's Research (MJFF), Natural Sciences and Engineering Research Council of Canada (NSERC), and Parkinson Canada; consultancy fees from Cure Ventures, Ipsen, Knight Therapeutics, Right Brain Bio, and UCB; and honoraria from the Canadian Movement Disorders Society (CMDS), Critical Path for Parkinson's (CPP), International Parkinson and Movement Disorder Society (MDS), and IOS Press. D.G.S. is a member of the faculty of the University of Alabama at Birmingham and is supported by endowment and University funds. Dr. Standaert is an investigator in studies funded by AbbVie, Inc., the American Parkinson Disease Association, The Michael J. Fox Foundation for Parkinson Research, The National Parkinson Foundation, Alabama Department of Commerce, Alabama Innovation Fund, Genetech, the Department of Defense, and NIH grant P50NS108675. He has a clinical practice and is compensated for these activities through the University of Alabama Health Services Foundation. He serves as Deputy Editor for the journal *Movement Disorders* and is compensated for this role by the International Parkinson and Movement Disorders Society. In addition, since January 1, 2022 he has served as a consultant for or received honoraria from AbbVie Inc., Alnylam Pharmaceuticals, Appello, Biohaven Pharmaceuticals, Inc., BlueRock Therapeutics, Coave Therapeutics Curium Pharma, F. Hoffman-La Roche, Eli Lilly USA, Sanofi-Aventis, and Theravance, Inc. He has also received book royalties from McGraw-Hill Publishers. R.T. received consultancies from KAN Research Institute, Inc.; grants/research support from Sumitomo Dainippon Pharma Co., Ltd., Eisai Co., Ltd., and Kyowa Kirin Co., Ltd.; grants from Japan Agency for Medical Research and Development (AMED), JSPS, and Ministry of Education Culture, Sports, Science and Technology Japan; and honoraria from Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Eisai Co., Ltd., and Ono Pharmaceutical Co., Ltd. M.V. has received research support from Aligning Science Across Parkinson's (ASAP, CRN), The Michael J. Fox Foundation for Parkinson's Research, The Ministry of Science and Innovation of Spain, the EU Joint Programme Neurodegenerative Disease Research (JPND), and La Caixa Bank Foundation. B.M. has received honoraria for consultancy from Roche, Biogen, and AbbVie. B.M. is member of the Executive Steering Committee of the Parkinson Progression Marker Initiative of The Michael J. Fox Foundation for Parkinson's Research and has received research funding from Aligning Science Across Parkinson's disease (ASAP, CRN). P.S. has received honoraria for consultancy from Lundbeck and AbbVie and funding from Aligning Science Across Parkinson's (ASAP, CRN), Lexa/Nordstjernan, Knut and Alice Wallenberg Foundation, and the Swedish Medical Research Council.